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Development of nanostructures as MR contrast agent will significantly improve 
the field of disease diagnostics. Contrast agents such as iron oxide nanoparticles are less 
toxic compared to more commonly used gadolinium based agents. A subclass of iron 
based nano particles are super paramagnetic iron oxide nano particles, (SPIOs) which are 
widely studied MR contrast agents useful in both imaging and drug delivery applications. 
In this work, SPIOs were synthesized and characterized and used for cellular tracking and 
multi modal labeling. A new solvent exchange method was utilized to coat different core 
size iron oxide nano particles. SPIOs were characterized for in-vivo imaging using MR 
and they had a very uniform size distribution which was determine using dynamic light 
scattering (DLS) and transmission electron microscopy. Furthermore, blood circulation 
half-life of 16nm SPIOs were determined through tail vein injection.  
SPIOs have many applications among which is the in vivo tracking of stem cells 
which is critical for determination of stem cells fate after injection. Magnetic Resonance 
(MR) as a non-invasive method can provide significant information about the fate of the 
cells as well as determination of the success rate of therapeutic cellular deliveries. 
Mesenchymal stem cells can be loaded with super paramagnetic iron oxide nano particles 
(SPIOs) and have their movements followed once planted in vivo. We present our 
findings on the effect of SPIO concentration and stem cell density on the MR signal and 
transverse relaxation time. Our preliminary results indicated that SPIOs do not cause 
mesenchymal stem cell cytotoxicity and do not affect proliferation ability up to 200 






internalization and the result showed that SPIOs will stay inside the cell. We also found 
that the contrast increases in a concentration dependent manner. Our results suggest that 
using MR with low concentration of SPIOs is a novel and promising method for 
tracking of mesenchymal stem cells. 
In this work SPIOs were also labeled with 64Cu to investigate their potential for multi 
modal positron emission tomography (PET) MR imaging. Dual modality PET MR SPIO 
contrast agent can be synthesized to image diseases such as cancer and atherosclerosis. 
The advantage is the non-invasive and early detection of disease at molecular lever 
before it has spread to late stages or in case of the atherosclerosis before the plaque has 
blocked the vessel. To develop a multi modal contrast agent, a positron emitter, 64Cu 
(half-life of 12.701 ± 0.002 hours), was used in labeling and synthesis was performed all 
in one step with the addition of 64Cu chelator, 14-PE DTPA followed by radiolabeling for 
both 6.5nm SPIO and 17nm SPIO. After labeling and purification with the desalting 
column, the amount of dissociated 64Cu in the solution was determined using radio thin 
layer chromotagraphy (TLC) and the particle was shown to have minimum amount of fee 
64Cu. Serum stability of labeled SPIO was determined in vitro by incubating 64Cu-labeled 
SPIOs in mouse serum at 37 °C for 24 hr with constant shaking. Radio TLC result then 
revealed that 64Cu stays bounded to the SPIO after 24 hours in mouse serum. This means 
that 64Cu labeled SPIO has a great potential as a dual modality contrast agents and further 





CHAPTER 1: SYNTHESIS AND CHARACTERIZATION OF SPIO 
 
 
Development and characterization of a biocompatible magnetic resonance (MR) 
contrast agent with sufficient in vivo circulation half-life has been a challenge for many 
years. Among the currently existing MR contrast agents the most widely used in the 
clinic is the gadolinium(III) chelate commonly referred to as “gado”[1]. Although it is 
widely utilized and studied, it is believed that it may cause nephrogenic systemic fibrosis 
(NSF) in patients with end stage renal disease (ESRD)[2, 3]. This can be prevented by 
using iron oxide based contrast agents such as super paramagnetic iron oxide 
nanoparticles.  
MR imaging modality with its non-invasive methods is characterized by high 
resolution of soft-tissues without the dangers of radiation exposure. The signal intensity 
of MR imaging is determined, in part, by longitudinal relaxation time (T1) and transverse 
relaxation time (T2). Since MR imaging captures both healthy and pathological tissues, 
contrast agents such as paramagnet gadolinium are used to help visualize and distinguish 
between the two tissue types. However, some contrast agents are more effective in T1 
while other contrast agents more effective in T2. For example, gadolinium contrast agents 
are T1 contrast agents since the percentage increase in 1/T1 in tissue is much greater than 
1/T2 [1].   
Iron contrast agents are also used in MR imaging and are best visualized with T2 
weighted scans. Super paramagnetic iron oxide nano particles, (SPIOs) are widely 
studied MR contrast agents useful in both imaging and drug delivery applications. SPIOs 
have two basic components: (1) the core which is made of inverse spinel crystal 




increase the circulation half-life of the SPIO and to also make them biocompatible for in 
vivo applications. In our lab the iron oxide cores were coated with polymers such as 
poly(ethylene glycol) PEG. The two materials making up the core of SPIO are similar in 
crystal structure but Maghemite has lower saturation magnetization. 
Maghemite and magnetite crystal, which make up the core of the SPIOs, are the 
major factor in signal enhancement of these nano particles. The core crystal of SPIOs has 
unpaired electron pairs which align to give rise to the magnetic properties of the 
nanoparticle. Furthermore, the magnetite crystal at nanometer scale has single crystal 
domain that cause them to exhibit superparamagnetic behavior.  
SPIOs can be loaded with reporter molecules such as radionuclide and targeting proteins 
and peptides. In our lab, we have developed a new method for synthesizing SPIOs with 
tight control over their diameter and surface chemistry [4]. 
 
Figure 1.1. Schematic diagram of SPIO structure. The core is made of iron oxide with a 







The significance of this new coating method is that it allows for the SPIOs to be 
functionalized for targeting and imaging purposes. Therefore, it is a better way to 
distinguish healthy from pathological tissue. 
 
1.1  Developing SPIO as an MR contrast agent 
 
Iron oxide core of 16.5 average diameter was synthesized in our lab with a coating of 
oleic acid and oleic amine to stabilize the core. The thermal decomposition method which 
was used to make the core improves the size distribution of nanparticles. Figure 1.2 
shows a TEM image of the 16.5nm iron oxide cores synthesized. The core size of 16.5 
nm was obtained by employing controllable crystallization through thermodecomposition 




Figure 1.2. Iron Oxide Cores synthesized using thermodecomposition of iron complex in 





The cores were then coated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine- 
N-[methoxy(polyethylene glycol)] copolymer (DSPEmPEG). A novel solvent-exchange 
method was developed in our lab in which DSPE-PEG and iron oxide nanocrystals 
assemble in a solvent system with ascending solvent polarity. This method yields high 
quality SPIOs with much improved coating efficiency and size distribution [7]. Figure 1.3 
shows the TEM image of the coated SPIO. Images were obtained with JEOL JEM-1210 
Transmission Electron Microscope.  
 
 
Figure 1.3. TEM images of the coated SPIO using the dual-exchange solvent method. 
SPIOs were negatively stained with phosphotungsic acid to show a white layer 
surrounding the iron oxide cores indicating the DSPE-mPEG2000 coating layer. 
 
 
As it is shown in the image, the SPIOs are very uniform in size. The PEG coating can be 
clearly seen as a white layer surrounding the iron oxide core. This coating was performed 





1.2 Particle Characterization 
 
 After the synthesis of any type of nano-structure, it is crucial to characterize it. 
The size distribution of the SPIOs was determined using DLS and TEM imaging. This 
ensured that the particle population was uniform. The T2 relaxivity was then determined 
using a Bruker minispec T2 analyzer. Circulation half-life was also determined by 
intravenous injection of Balb/C mice.  
 
1.3 Particle Size 
 
The size distribution of the SPIOs were determined using a DynaPro DLS 
(dynamic light scattering) instrument. Figure 1.4 shows the DLS result for 16.5nm cores 
and the SPIOs coated with DSPE-mPEG2000. As it is shown by the red curve, after 
coating, the average size increased to 30.8 nm. Experiments reported here were 
performed with 200-fold averaging and a 40-s integration time. The laser power was 
adjusted so that all the samples gave scattering amplitude of ~106 counts s-1. The 



























Figure 1.4. Size distribution of iron core and coated SPIO using a DynaPro NanoStar 
Dynamic Light Scattering Instrument 
 
 
The differences in signal intensities among tissues with intrinsically different 
relaxation parameters are the basis for MR imaging. The presence of magnetic nano 
particles disturbs the magnetic field homogeneity and enhances tissue T2 relaxation. 
SPIOs are negative contrast agent as they make the tissue or sample containing them 
darker by decreasing the T2.  
The T2 relaxivity (defined as 1/T2 normalized by molar concentration of Fe atoms) of the 
SPIOs were measured with two core sizes (6.5 nm and 14 nm) and DSPE- PEG 2000 at 
40 oC. The T2 relaxivity for 14 nm was 184 s-1 mM-1 Fe and decreased to 114 s-1 mM-1 Fe 
for the 6.5 nm core. Due to increased mass magnetization and core size, the 14 nm SPIOs 
consistently showed higher T2 relaxivity than the 6.5 nm SPIOs with the same coating. 
Using a larger core size particles, therefore, will yield better results when used for MR 




1.4 Circulation Half-life 
 
Since the SPIOs are developed to be injected in-vivo they need to have a long 
blood circulation half-life so they can create a contrast. Circulation half life is an 
important parameter as the particle needs to be retained in the blood for a period of time 
to allow for imaging and accumulation of enough SPIOs inside the organ of interest. On 
way of improving the half life is through surface chemistry which has a strong influence 
on how long the particle circulates in the blood. The SPIOs are known to primarily clear 
out of circulation due to the phagocytosis of RES (Reticulou Endothelial System) in the 
liver and spleen. Micrometer sized constructs are cleared immediately following 
intravenous injection, however, pegylated nanoparticles such as SPIOs will have a much 
longer circulation in the blood[8-10]. Poly Ethylene Glycol (PEG) is an FDA approved 
coating which is used in our coating to reduce the affinity for the RES and improve 
stability. This will slow the uptake pathway and improve blood circulation half life.  
To determine blood circulation half-life, 0.05ml of 16nm core SPIO at a concentration of 
1 mg/ml was injected through the tail vein in 2 Balb/C mice. Blood was drawn by tail 
nicking at 5min, 30min, 60 min, 120min, 180 min and 240 min. Figure 1.5 shows the 
corresponding data. The initial time data point on the graph is calculated based on the 
known weight of the mouse and the assumption that blood volume is 8% of the mouse 



















Figure 1.5. Blood clearance of 17nm SPIOs after intravenous injection. Blood samples 
were collected by tail nicking at 5, 30, 60, 120, 180 and 240 minutes post injection of 
SPIO. Amount of iron in the blood was quantified with a Ferrozine Assay. Data is shown 




Based on the data shown in Figure 1.5, it was determined that the blood circulation half 
life of the 17nm SPIOs was 29.36 minutes. Therefore, the addition of the PEG on the 
surface of the SPOIs can significantly increase their circulation half life. PEG is believed 
to decrease RES uptake of the SPIOs by increasing the hydrophilicity of the SPIO’s 
surface. This will reduce the non-specific interaction of SPIOs with RES cells in vivo. To 
see the effect of SPIO core size on blood circulation half, 6.5nm and 14 nm core size 
SPIOs were coated with PEG 2000. Intravenous injection of 0.15 ml of 1mg/ml SPIOs 
were performed on two Balb/C mice. Blood circulation half-life of 14 nm SPIO was only 













Nano particles can be loaded to cells of many type ex-vivo in order to track their 
movement once implanted. Traditional methods of cell tracking includes the use of 
invasive chamber models with intravital microscopy [11] or using flow cytometry of the 
fluorescently labeled cells from excised tissues [12]. In-vivo MR tracking of cells can 
provide valuable information and be useful in the fields of cancer therapy, cardiovascular 
disease, and neuro-imaging. Stem cells can be loaded with SPIOs and have their 
movement followed once planted in vivo. MR tracking of the cells is a non-invasive 
method to determine the success rate of therapeutic cellular deliveries. Stem cells 
migration and dynamics within individual animal model can be observed with high 
resolution MRI for a long period of time [13]. SPIOs are also used to track cells used for 
stem cell therapy and monitoring the fate of dendritic cells administered as a cancer 
vaccine. Since cells do not always localize in the target organ once delivered, in vivo MR 
tracking of these cells will allow for the better therapeutic design and administration of 
these cell based therapies. Simple incubation with SPIO can label many types of cells 
including monocytes and macrophages [14]. 
Smaller concentration of SPIO can produce MRI contrast compared to gadolinium 
contrast agents. Toxicity is also less of the problem since there is iron already present in 
the body and SPIOs can be naturally recycled after imaging is performed. It is however 
important to determine the sensitivity of the MRI signal to SPIO and also determine the 




Lewin and collegues reported the observation of single cell in tissue samples using 
magnetic nanoparticles[15]. Progenitor cells have been tracked in vivo using Tat peptide-
derived magnetic nanoparticles. The nanoparticle consist of a crosslinked (CL) dextran 
coated 5nm iron oxide core. The dextran coating was also reacted with DTPA to allow 
labeling with 111In used for nuclear imaging. The achieved labeling efficiencies for the 
different cells ranging from 10 to 30 pg of superparamagnetic iron per cell equivalent of 
up to 0.5- 2 x 107 nanoparticles/cell [15].  
Heymer and colleagues used very small superparamagnetic iron oxide particles (VSOPs). 
They observed the endocytosis in human mesenchymal stem cells using histology and 
quantified the amount of iron uptake by mass spectrometry. It was also found that cell 
viability and proliferation potential of the cells was not affected when compared with 
unlabelled cells [16]. 
 
2.2 SPIO DELIVERY  
 
The adherent hMSCs were cultured in MEA-Alpha supplemented with 
Gentamycin at 12.5 mg per 500 ml, 10% FBS, and 200mM L-Glutamine in a humidified 
5% CO2 atmorphere at 37 oC in 75 cm2 flasks. A study was performed to determine the 
optimal time of incubation and concentration of hMSCs labeled with SPIOs in vitro. To 
treat the cells with the nanoparticles, 50,000 cells per well were seeded into 24-well plate 
for iron content measurement. The cells were cultured for 24 h, and then the media 
containing different concentrations of the nanoparticles were exchanged into wells, and 






2.3  Measurement of Cell Iron Content 
 
Human Mesenchymal Stem Cell line was then cultured with different 
concentration of 16.5nm core size SPIO and different time of incubation (labeled with 
media containing Fe: 50 μg/ml, and 100 μg/ml and for 1hour, 3hr, 24hour). The amount 
of SPIOs in cells was quantified by using a Ferrozine Assay developed in our lab. After 
the treatment with 16.5nm SPIOs, cells were washed three times with PBS, collected in a 
1.5-mL tube, and counted using hemacytometer. Cell solutions were then  precipitated by 
centrifugation, resuspended in 50 μL of culture media. The cells were treated with 50 μL 
of hydrochloric acid, and incubated at 37 oC for 1 h. To neutralize the acid, 240 μL of 2N 
NaOH was then added, followed by 50 μL of 4N AA, and 110 μL of 5% HH. The 
solution was centrifuged for 15min at 22000 g, and 50 μL of the supernatant was 
removed and mixed with 50 μL of Ferrozine or color solution in the well in the NUNC 
384 plate. The plate was read after 40 minutes using a Safire TECAN plate reader. A 
blank control cell sample was used to confirm the absence of iron contamination in the 
tested cells. The average iron content per cell was calculated by dividing the total iron 
content of the sample by the number of cells in the sample. The uptake of SPIOs was not 
significant within the first 3 hours at both 50 μg/ml and 100 μg/ml. The uptake was 
increased to 15.5 pg/ml per cell fo the 50 μg/ml and 17.6 pg for the 100 μg/ml. This 










2.4 CYTOTOXICITY ASSAY 
 
Although the iron oxide core of SPIO is harmless at low doses and the PEG 
coating is biocompatible, before injecting hMSCs with SPIO and performing in-vivo 
studies it is important to determine the cytotoxicity and cell viability after a long 
incubation time[18]. Therefore, after delivering SPIOs to the hMSCs, their viability was 
determined using trypan blue staining. Equal volume of Trypan blue and cell solutions 
were incubated for 10 minutes. The number of unstained (viable) and stained (nonviable) 
cells were counted separately in the hemacytometer. To obtain the total number of viable 
cells per ml of aliquot, the total number of viable cells was multiplied by 2 (the dilution 
factor for trypan blue). To obtain the total number of cells per ml of aliquot, the total 
number of viable and nonviable cells was add up and multiplied by 2. The percentage of 
viable cells was then calculated as follows: 
 
  %   
        
       10 
 
To see the effect of SPIOs on cell viability, hMSCs were incubated with different 
concentration of SPIO (labeled with media containing Fe: 0 μg /ml, 50 μg/ml, 100 μg/ml, 
and 200 μg/ml) for 24 and 36 hours. Figure 2.1 shows the result of the Trypan Blue 






















Figure 2.1. Cell Viability Assay of hMSCs after incubating with SPIO (labeled with 
media containing Fe: 0 μg /ml, 50 μg/ml, 100 μg/ml, and 200 μg/ml) for 24 hours 
 
As it is shown in Figure 2.1, cell viability was not greatly affected at 50 μg/ml and 100 
μg/ml concentration. Even at the 200 μg/ml concentration of Fe, the viability remained at 
94% after 24 hour incubation.  
Figure 2.2 shows the result of the Trypan Blue viability assay on hMSCs after 36 hours 
incubation with SPIOs. At 50 μg/ml and 100 μg/ml, toxicity was minimum and it 
increased to 6% at 200 μg/ml. This result agrees with the previously reported studies of 


























Figure 2.2. Cell Viability Assay of hMSCs after incubating with SPIO (labeled with 
media containing Fe: 0 μg /ml, 50 μg/ml, 100 μg/ml, and 200 μg/ml) for 36 hours. 
 
 Trypan Blue is a dye exclusion method but it is subject to the problem that viability is 
being determined indirectly from cell membrane integrity. Thus, it is possible that a cell’s 
viability may have been compromised (as measured by capacity to grow or function) 
even though its membrane integrity is maintained. Therefore, it was necessary to also test 
cell proliferation and for that reason PrestoBlue cell proliferation assay was used to test 
the viability and proliferation of hMSCs incubated with SPIOs. This reagent uses the 
reducing power of living cells to quantitatively measure the proliferation of cells. Figure 
























Figure 2.3. Cell Proliferation Assay (PrestoBlue)of hMSCs after incubating with SPIO 
(labeled with media containing Fe: 0 μg /ml, 50 μg/ml, 100 μg/ml, and 200 μg/ml) for 48 
hours 
 
As it is shown cell proliferation was greatly affected by the high concentration at 200 
μg/ml. Based on this result it is best to either use the 50 μg/ml or the 100 μg/ml 
concentration. The amount of iron uptaken by the cells was quantified using Ferrozine 
colorimetric assay and it was found that after 24 hours, 15.5 pg of SPIO will be uptaken 
per cell. This agrees with previous reports. 
 
2.5      CONFOCAL MICROSCOPY 
 
To further investigate labeling efficiency and intracellular localization, several studies 
were performed with hMSCs. In this study, 100 ug/ml of DiI labeled SPIOs were 
incubated with hMSCs for 24 hours. Cell nucleus was stained using Hoescht and confocal 
microscopy analysis confirmed that SPIOs were internalized into hMSCs. The particles 






Figure 2.4. DiI labeled SPIOs inside the hMSC. Figure a. shows the DiI labeled SPIOs 
alone. Figure b. shows the cell nucleus labeled with Hoescht and Figure c. shows both 
cell nucleus and the particles inside the hMSCs. 
 
Endocytosis is thought to be the main mechanism by which nanoparticles enter the cells. 
However, it is believed that nanoparticles will also get out of the cell through 
transcytosis.  
Flow Cytometry was also performed with DiI labeled SPIOs which were internalized into 








Figure 2.5. Flow Cytometry of the DiI labeled SPIOs inside the hMSC. Figure a. shows 
the hMSCs alone. Figure b. shows the hMSCs labeled with SPIOs. 
 
Based on the confocal microscopy images and the flow cytometry data it was found that 
the SPIOs do indeed get internalized into the cell cytoplasm. The question is, however, if 
they get out of the cell once they are injected in vivo for imaging or therapeutic purposes. 
An experiment was designed to answer this question and also determine the rate at which 
SPIO get out of the hMSCs. The cells were incubated with 6nm SPIO for 1 hour on the 
magnet and the rest of the media containing nano particles was removed. The cells were 
washed with cold PBS three times to remove all the SPIOs that did not get internalized 
into the hMSCs. 2ml of Culture media was then added to the cells. A 50 ul sample of 
culture media was removed at times, 0, 1 hour, 3 hours, and 24 hours. At each time point 
Ferrozine Assay was used to determine the concentration of the SPIOs in the culture 
media. Cells incubated with culture media served as control in this study. Figure 2.6 
































Figure 2.6. SPIO release out of hMSCs over 24 hour time period. The concentration of 
iron in the culture media was not increased significantly over time. 
 
As shown in Figure 2.6, it was found that the amount of SPIO released from hMSCs is 
negligible. Data shows that the slight increase in iron concentration could be due to the 
endogenous iron as shown in the red control curve. 
 
2.6 MRI of hMSCs 
 
To determine the detection efficiency of MRI the 14.5nm SPIOs were incubated 
with hMSCs on the magnet at a concentration of 100 ug/ml for 1hour. After delivery, the 
Cells were washed with cold PBS three time, then trypsinized. The final sample 
contained 30ul of cell sample suspended into 30 ul of the 1% agarose gel. The wells were 
imaged with a 7T Bruker small animal MRI using a spin-echo sequence. The result is 
shown in Figure 2.7. The T2 map shows that the increase in concentration of the SPIO 




observed that for the same concentration of the SPIO, T2 decreases as the number of cells 
increases from 2K to 14K.  
 
Figure 2.7. T2 map of the SPIO delivered hMSCs embedded in 0.5% agarose gel. 
 
Chemical Exchange Saturation Transfer (CEST) is an MRI molecular imaging tool that 
helps resolve different signals arising from protons on different molecules. The location 
of the CEST agent can be revealed by saturating a particular proton signal that is in 
exchange with surrounding water molecules. Figure 2.8 shows the width of the z 





Figure 2.8. The width of the Z-spectrum using CEST method. Contrast increases in a 
concentration dependent manner. From right to left, this indicates the uptake of SPIOs by 
the hMSC. 
 
The width of the Z-spectrum is correlated with the concentration of the SPIOs. As it is 
shown, the highest concentration of the SPIO is at the well with 14k cells and the initial 
concentration of 100ug/ml. The effect of increasing cell density is clearly observed for 
the 100 ug/ml row. As the cell density increases the width of the Z-spectrum also 
increases indicating an increase in SPIO concentration.  
To observe and understand the effect of cell density and SPIO concentration on the MRI 














Figure 2.9. T2 Calculated Image of cells suspended in agarose gel.  
 
The result demonstrates that the 14.5 nm SPIO labeled hMSC can affect the T2. Only 





















CHAPTER 3: DUAL MODALITY PET/MR CONTRAST AGENT 
 
Positron Emission Tomography (PET) was created in 1970s to combine early 
biochemical assessment of pathology with the precise localization through the use of 
nuclear medicine and computerized image reconstruction. In this technique a biologically 
active chemical compound is labeled with a radioactive ispotope that decays by emitting 
a positron. The positron then travels a small distance before combining with an electron 
and emitting two back to back gamma photons [19]. This technology has a very high 
sensitivity compared to other image modalities and PET images can be interpreted to 
provide regional assessment of biochemical processes. The lack of anatomical 
information was solved by combining PET with high resolution anatomical imaging like 
Computed Tomography (CT) in the late 1990s [20]. However, increased use of the CT 
which  is associated with ionizing radiation has led to concern among the radiology 
community (radiologists, medical physicists, and manufacturers) [21]. Combination of 
PET and MR is an attractive option since MR provides high anatomical resolution 
without the harmful effects of ionizing radiation and much effort has been invested in 
developing a PET/MR diagnostic imaging system [22, 23]. To better visualize the 
existence of malignancy with this system, a dual modality contrast agent such as radio-
labeled SPIO is developed. Dual modality PET MR SPIO contrast agent can be 
synthesized to image diseases such as cancer and atherosclerosis. The advantage is the 
non-invasive and early detection of disease at molecular lever before it has spread to late 
stages or in case of the atherosclerosis before the plaque has blocked the vessel. There are 




The radionuclide used for PET imaging has a limited half-life; also chemical conjugation 
methodologies must be developed to ensure that the particle stays intact after it is 
exposed to the harsh environment inside the body [24]. 
The unique decay properties of 64Cu make it useful as a radiotracer for PET. It has 
a longer half life (12.701 ± 0.002 hours) compared to FDA approved 18F and decays by 
17.86%  positron emission, 39.0% by beta decay, 43.075% by electron capture and 
0.475% gamma radiation/internal conversion. It can also be produced in high yield and 
high specific activity which is required for in-vivo PET imaging [25].  
Figure 3.1 shows the schematic of PET/MR SPIO. The chelator 14-PE DTPA will 
not dissociate due to the strong hydrophobic interaction between the PEG chain and the 








Figure 3.1. Schematic of PET/MR contrast agent with 64Cu chelated by 14-PE DTPA 
and SPIO.  
 
3.1 Dual Modality Nanoparticles for PET MR Imaging 
 
Jarrett et al has recently reported on a dual modality contrast agent made of 64Cu 
labeled dextran sulfate coated iron oxide nanoparticles. These nanoparticles were targeted 




chelator DOTA was used to attach 64Cu to the particle and nanoparticles were purified by 
size exclusion chromatography (SEC) to yield CLIO-DOTA (64Cu). Separate PET and 
MR images were obtained 24 hours after contrast agent injection on ApoE-/- mice. The 
images were then coregistered and the three-dimensional volumes corresponding to probe 
uptake were traced and it was observed that the MR signal intensity was decreased. The 
contrast-to-noice ratio (CNR) at the aortic valve was increased by 68±10% [26].  
 
3.2 Synthesis of DTPA SPIO 
 
 Reactions were performed in oven-dried (140 oC) or flame-dried glassware under 
an atmosphere of dry air. Iron oxide cores were synthesized in the lab using a new 
method developed to control size and coating properties of the cores. Synthesis was 
performed using the novel solvent-exchanged method developed in our lab in which iron 
oxide nanocrystals were coated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-
N-[methoxy(polyethylene glycol)] copolymer (DSPEmPEG) and 1,2-ditetradecanoyl-sn-
glycero-3-phosphoethanolamine-N-diethylenetriaminepentaacetic acid (DMPE-DTPA) at 
the same time. This method eliminates one step of the conjugation and the final product 
was then used in radio-labeling.  
 Before the start of the synthesis it was necessary to determine the amount of DMPE-
DTPA required for the particle to have at least an average of 30 chelator per particle. 
Assuming 50% efficiency in radio-labeling, on average 15 64Cu per particle is necessary 
to produce a good PET signal. Therefore, a Malachite Green Phosphate detection kit was 
used to quantify the amount of DSPE-mPEG density on the surface of SPIOs. This assay 
will measure the phosphate concentration which will be correlated to amount of PEG on 




Aliquots of 100 μl SPIO solutions were evaporated under vacuum and 500  µl of 70% 
perchloric acid was added to each sample and the mixture was heated at 160°C for 20 
minutes in an oil bath. 580 µl of 10 M NaOH solution was then added to neutralize the 
pH. The concentration of phosphate in the solution was quantified with a Malachite green 
phosphate detection kit (R&D Systems). The assay was validated with solutions 

























Figure 3.2. PEG Density on the surface of the SPIOs. The loading ratio of PEG per iron 
was changed from 1 to 1 to 1 to 4. 
 
As it is shown the number of PEG per SPIO increased by increasing the loading ratio. 









3.3 Radiolabeling of DTPA SPIO with 64Cu 
 
Radiolabeling was performed for both 6.5nm SPIO and 17nm SPIO. DTPA SPIOs 
(0.25 mg in 250 μL) were incubated with 64CuCl2 (1.75 mCi in 2.2 μL, 0.1 M HCl) in 
0.1 M ammonium acetate buffer (pH 5.5) at 37 °C for 1 hr in a thermomixer. A glass test 
tube was used for reaction vessel. The temperature of the thermo mixer was stabilized 
one day before the experiment. Then 5 μL of 10 mM EDTA was added into the solution 
and the mixture was placed in the thermo mixer at 37 °C for 5 min with mixing to 
remove nonspecifically bound 64Cu, followed by purification using a centrifugal 
desalting column (Pierce Biotechnology, Inc., Rockford, IL). To determine the amount of 
dissociated Cu-64 in the solution, TLC was performed before purifying with the desalting 










Figure 3.3. TLC result for Cu-64 SPIOs. The peak at 60 cm indicates there are free 64Cu 
in the solution.  
 
 
Desalting column was used twice until all the free 64Cu was removed and the solution 
only contained radio-labeled SPIOs. The TLC result after the first and second desalting is 







Figure 3.4. TLC result for Cu-64 SPIOs after the first and second desalting. The graph on 
the left shows that after the second desalting all the free 64Cu is removed and the solution 
only contains radiolabeled SPIOs.  
 
 
Labeling yield was determined by radiochemical thin layer chromatography (radio-TLC). 
Figure 3.5 shows the TLC silicagel paper marked at the solvent front. A small amount of 
the of the 64Cu labeled SPIO solution was applied to an ITLC-SG plate (Pall Corporation, 
East Hills, NY) and developed using a 1/1 mixture (v/v) of ammonium acetate (10% 
w/v)/ methanol. The TLC plate is then measured using Raytest system (model Rita Star, 
Germany). Labeled 64Cu should stay at the spotting point (Rf 0) and the nonspecifically 








Figure 3.5. TLC silicagel paper showing the location of the SPIO sample. 
 
3.4 Serum Stability of 64Cu-labeled SPIO 
 
 Before injecting the 64Cu-labeled SPIO into the mice, it is necessary to determine 
the serum stability in vitro. This test was performed by incubating 64Cu-labeled SPIOs in 
mouse serum at 37 °C for 24 hr with constant shaking. The samples were then subjected 
to radio TLC analysis after 0, 1, 3, 6, and 24 hr incubation to measure the amount of 
activity dissociated from 64Cu-labeled SPIO.  Figures 3.6 and 3.7 show the TLC results 










Figure 3.6. TLC result for 64Cu labeled SPIOs incubated in mouse serum for 3 hours with 




Figure 3.7. TLC result for Cu-64 SPIOs incubated in mouse serum for 24 hours with 





Although there is no indication that there is free 64Cu dissociated from the SPIO in the 





























CHAPTER 4: DISCUSSION, CONCLUSION AND FUTURE WORK 
 
 
4.1 Discussion and Conclusion 
 
The problem with all nano materials injected systematically is their relatively 
short circulation half life preventing long term imaging. To improve the circulation half 
life we coated our particles with PEG which is a synthetic hydrophilic polymer and 
serves as a barrier preventing interactions with plasma opsonins. We then compared the 
T2 relaxivity and circulation half life of 6.5 nm and 14 nm SPIOs to determine the best 
candidate for imaging. Based on the T2 relaxivity results, the large SPIOs will create 
higher contrast in MR and they have an advantage of higher surface to volume ratio. This 
means that they can be loaded with higher number of positron emitters which also yields 
better sensitivity in PET imaging. The disadvantage of using larger SPIO compared to the 
small one is their poor circulation half life however the time is still long enough to create 
contrast. 
Our preliminary result of cellular studies indicates that SPIOs can be easily 
delivered into the cells and imaged with MRI. The concentration of 50 μg/ml is optimum 
for initial incubation and results in minimal toxicity to the cells. The minimum number of 
cells that were able to decrease the T2 time was 2000 hMSCs embedded in agarose gel. 
The noninvasive tracking of hMSCs to understand their distribution in-vivo will have 
significant impact on clinical imaging and therapeutic applications.  
We were able to successfully label SPIO with 64Cu with very high labeling yield. 
The large surface area of the SPIO enabled labeling with high specific activity which will 
greatly increase the sensitivity of the detection. The serum stability experiment revealed 




4.2 Future Work 
 
We recently acquired a new AKTA Purifier equipped with a UV detector and 
fitted with an in-line radioisotope detector.  Future works include verifying the labeling 
yield and also the RCP (Radio Chemical Purity) with the AKTA Purifier system. It is 
then necessary to move on to in-vivo mouse model to determine blood circulation half-
life and biodistribution of the 64Cu-labeled SPIO using both small animal PET imaging 
and a gamma counter to determine activity in organs such as liver, spleen, kidneys and 
heart. We will further investigate the effect of particle size on biodistribution and blood 
circulation using PET imaging.  
For the cell tracking project, future work includes delivering 64Cu-labeled SPIO to 
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